organ-transplant
(2)
CareDx Made Transplant Care Less Invasive. Then Its Own Business Needed Surgery.
The transplant diagnostics company turned fragments of donor DNA into a recurring-care business. A 2023 reimbursement shock forced a reset - and revealed a playbook built on narrow markets, repeat tests, and one very deep customer relationship.
eGenesis
eGenesis is a Cambridge, Massachusetts clinical-stage biotechnology company using multiplex CRISPR gene editing to engineer pig organs that the human body will accept. Its EGEN platform makes dozens of edits to a porcine genome at once - removing pig antigens, adding human genes, and inactivating embedded retroviruses - to create kidneys, livers, and hearts intended to ease the global organ shortage. In 2024 its lead candidate became the basis of the world's first gene-edited pig kidney transplant in a living patient, and in 2025 the FDA cleared it for a formal clinical trial.